Search Results

Biologica Technologies, developers and marketers of ProteiOS® growth factor and OsseoGEN® cellular bone matrix, announced two significant, separate agreements signed with Premier Inc. and Academy Medical.

Advanced Biologics (known commercially as Biologica Technologies), a California-based company known for their innovative biologic solutions, announced today their successful merger with Isto Biologics, a global leader in regenerative and autologous therapies.

Biologica Technologies, developers and marketers of ProteiOS® growth factor and OsseoGEN® cellular bone matrix, announced today the podium presentation, ‘Retrospective assessment of radiographic outcomes after implantation of a novel allograft growth factor combined with scaffold in patients undergoing XLIF, LLIF, and TLIF procedures’

Biologica Technologies, developers and marketers of ProteiOS ® growth factor and OsseoGEN ® cellular bone matrix, announced today the early topline results from a retrospective, multicenter study evaluating the safety and effectiveness of ProteiOS in foot and ankle arthrodesis (fusion) procedures.

The FDA’s guidance on AI in drug development points to potentially life-threatening consequences of the technology, highlighting the importance of providing the regulator with detailed information regarding models’ development and maintenance.

Biologica Technologies, developers and marketers of ProteiOS®, announced today that they have been recognized as one of the Top 10 MedTech Startups in 2019 by MedTech Outlook Magazine.

Biologica Technologies, LLC is excited to announce the relocation and expansion of its head office to a larger facility within the same city of Carlsbad, CA.

Biologica Technologies, LLC (the “Company” or “Biologica”) announced today that they will be showcasing their latest clinical data for ProteiOS growth factor at this week’s Midwest Podiatry Conference held in Chicago, IL.